NEW
YORK, Sept. 5, 2023 /PRNewswire/
-- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative
oncology company focused on the discovery and development of
selective cancer therapies to treat patients across a range of
solid tumors with significant unmet medical needs, today announced
that Joseph Ferra, Chief Executive
Officer of Elevation Oncology, will present at the H.C. Wainwright
25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 12:00 pm ET.
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class antibody drug conjugate (ADC)
designed to target Claudin 18.2, a clinically validated molecular
target. EO-3021 selectively delivers a cytotoxic payload directly
to cancer cells expressing Claudin 18.2. Elevation Oncology is
evaluating EO-3021 in a Phase 1 study in patients with advanced,
unresectable or metastatic solid tumors likely to express Claudin
18.2 including gastric, gastroesophageal, pancreatic or esophageal
cancers. We are also exploring other opportunities through new or
existing partnerships and business development opportunities to
expand its novel oncology pipeline. For more information,
visit www.ElevationOncology.com
Elevation Oncology Investor and Media
Contact
Candice Masse,
978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301916143.html
SOURCE Elevation Oncology